Breaking news

Wizz Air Halts Israel Flights Amid Security Fears: Impact On Cyprus And Beyond

Wizz Air, a prominent low-cost European airline, has temporarily suspended its operations to and from Israel, citing escalating security risks in the region. This decision primarily affects flights between Tel Aviv and various European cities, including those connecting with Cyprus, a key market for the airline. The suspension underscores the volatile security environment in Israel, which has prompted Wizz Air to prioritise passenger safety above all else.

The suspension comes at a critical time for both the airline and travellers. Wizz Air has been steadily expanding its presence in the Eastern Mediterranean, with Israel being one of its key markets. The airline operates multiple routes between Tel Aviv and major European hubs, making this suspension a significant disruption for both business and leisure travellers.

For Cyprus, the impact is particularly notable given the close ties and frequent travel between the two countries. The suspension could lead to reduced connectivity and increased travel costs for passengers, as they may need to seek alternative airlines or routes. Moreover, the suspension may also affect tourism, a key sector for both Israel and Cyprus, especially during the peak travel season.

Wizz Air’s decision reflects the broader challenges airlines face in navigating geopolitical instability. The airline has indicated that it will continue to monitor the situation closely and provide updates as conditions evolve. Passengers affected by the suspension have been advised to check Wizz Air’s official channels for information on flight resumptions, refunds, or alternative travel arrangements.

This suspension is not unprecedented; airlines often adjust their operations in response to security threats, balancing the need to maintain service with the imperative of ensuring passenger safety. However, the timing and scale of Wizz Air’s decision highlight the growing concerns over security in the region and the potential ripple effects on international travel.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

eCredo
Uol
Aretilaw firm
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter